share_log

T2 Biosystems | 8-K: T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

T2 Biosystems | 8-K: T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

T2 Biosystems | 8-K：T2 Biosystems公布2024年第四季度和全年初步财务业绩
美股SEC公告 ·  01/07 22:09

Moomoo AI 已提取核心信息

T2 Biosystems achieved record product revenues of $2.3M in Q4 2024 and $8.3M for full-year 2024, representing YoY increases of 37% and 23% respectively, driven by record sepsis test sales. The company executed contracts for 27 T2Dx Instruments in 2024, with 23 for international markets and 4 for the U.S.The company secured significant commercial partnerships, including an exclusive U.S. distribution agreement with Cardinal Health for T2Dx Instrument and panels, and expanded its international distribution network to six new countries. Financial improvements included converting $30M of term loan into common stock, reducing debt and quarterly interest payments by approximately 80%.Notable regulatory achievements included FDA 510(k) clearances for expanded T2Bacteria Panel capabilities and pediatric testing for T2Candida Panel. The company plans to submit T2Resistance Panel for FDA 510(k) clearance in Q1 2025, while successfully defending a key European patent for its direct-from-whole blood detection method.
T2 Biosystems achieved record product revenues of $2.3M in Q4 2024 and $8.3M for full-year 2024, representing YoY increases of 37% and 23% respectively, driven by record sepsis test sales. The company executed contracts for 27 T2Dx Instruments in 2024, with 23 for international markets and 4 for the U.S.The company secured significant commercial partnerships, including an exclusive U.S. distribution agreement with Cardinal Health for T2Dx Instrument and panels, and expanded its international distribution network to six new countries. Financial improvements included converting $30M of term loan into common stock, reducing debt and quarterly interest payments by approximately 80%.Notable regulatory achievements included FDA 510(k) clearances for expanded T2Bacteria Panel capabilities and pediatric testing for T2Candida Panel. The company plans to submit T2Resistance Panel for FDA 510(k) clearance in Q1 2025, while successfully defending a key European patent for its direct-from-whole blood detection method.
T2 Biosystems在2024年第四季度实现了230万美元的创纪录产品收入，并在2024年全年达到了830万美元，分别同比增长了37%和23%，这一增长主要得益于创纪录的脓毒症检测销售。该公司在2024年签订了27台T2Dx仪器的合同，其中23台用于国际市场，4台用于美国。公司还签署了重要的商业合作伙伴关系，包括与卡地纳健康达成的T2Dx仪器和面板的独家美国分销协议，并将国际分销网络扩展到六个新国家。财务改善方面，包括将3000万美元的定期贷款转换为普通股，使债务和季度利息支出减少约80%。值得注意的监管成就包括FDA 510(k)批准扩展T2Bacteria面板功能和针对T2Candida面板的儿科测试。该公司计划在2025年第一季度提交T2Resistance面板的FDA 510(k)申请，同时成功维护其直接从全血检测方法的关键欧洲专利。
T2 Biosystems在2024年第四季度实现了230万美元的创纪录产品收入，并在2024年全年达到了830万美元，分别同比增长了37%和23%，这一增长主要得益于创纪录的脓毒症检测销售。该公司在2024年签订了27台T2Dx仪器的合同，其中23台用于国际市场，4台用于美国。公司还签署了重要的商业合作伙伴关系，包括与卡地纳健康达成的T2Dx仪器和面板的独家美国分销协议，并将国际分销网络扩展到六个新国家。财务改善方面，包括将3000万美元的定期贷款转换为普通股，使债务和季度利息支出减少约80%。值得注意的监管成就包括FDA 510(k)批准扩展T2Bacteria面板功能和针对T2Candida面板的儿科测试。该公司计划在2025年第一季度提交T2Resistance面板的FDA 510(k)申请，同时成功维护其直接从全血检测方法的关键欧洲专利。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Biodesix
    BDSX
    -- 1.030
    bioAffinity Technologies
    BIAF
    -- 0.710
    ProPhase Labs
    PRPH
    -- 0.540
    Grail
    GRAL
    -- 28.610
    燃石医学
    BNR
    -- 7.317
    解锁完整榜单
    热门中概股
    追踪最热门的中概股实时资讯。
    热门讨论
    中美谈话新契机，通胀不再？
    🎙️讨论： 1. 你认为特朗普上台后，对华政策将如何影响中国资产？ 2. 美股市场通胀风险下降，有哪些利好板块？ 展开
    中国将在未来一年采取"适度宽松"的货币政策，这是自2011年以来的首次转向宽松。